Why is msi problematic

Content on WhatAnswers is provided "as is" for informational purposes. While we strive for accuracy, we make no guarantees. Content is AI-assisted and should not be used as professional advice.

Last updated: April 8, 2026

Quick Answer: MSI (Microsatellite Instability) is problematic because it indicates DNA mismatch repair deficiency, which increases cancer risk. Specifically, MSI-high tumors account for approximately 15% of colorectal cancers and 20-30% of endometrial cancers. This genetic instability was first linked to Lynch syndrome in 1993, and testing for MSI status became standard clinical practice in the late 1990s. MSI-positive cancers often have poorer prognosis but may respond better to immunotherapy treatments like pembrolizumab.

Key Facts

MSI-high tumors represent 15% of colorectal cancers
MSI-high tumors represent 20-30% of endometrial cancers
MSI was first linked to Lynch syndrome in 1993
MSI testing became standard clinical practice in late 1990s
MSI-positive cancers may respond better to immunotherapy

Overview

Microsatellite Instability (MSI) refers to genetic alterations in short, repetitive DNA sequences called microsatellites, which occur due to defects in the DNA mismatch repair (MMR) system. This phenomenon was first discovered in the early 1990s when researchers identified it as the molecular basis of Lynch syndrome (hereditary nonpolyposis colorectal cancer). The National Cancer Institute established standardized MSI testing criteria in 1997, defining MSI-high tumors as those with instability in ≥30-40% of tested markers. MSI status has become a crucial biomarker in oncology, with clinical testing expanding significantly since 2000. By 2010, MSI testing was recommended for all colorectal cancer patients under age 50, and in 2017, the FDA approved pembrolizumab for MSI-high solid tumors regardless of cancer type, marking a major advancement in precision medicine.

How It Works

MSI occurs when the DNA mismatch repair system fails to correct errors during DNA replication, particularly in microsatellite regions—short, repetitive sequences of 1-6 base pairs that are prone to replication errors. Normally, MMR proteins (MLH1, MSH2, MSH6, PMS2) detect and repair these errors, maintaining genomic stability. When these proteins are deficient due to genetic mutations (germline in Lynch syndrome or somatic in sporadic cancers), errors accumulate, causing microsatellites to change length. Clinically, MSI testing involves comparing tumor DNA to normal DNA at 5-7 specific microsatellite loci. If ≥2 loci show instability, the tumor is classified as MSI-high. This testing can be done via PCR-based methods or immunohistochemistry for MMR protein expression. The process typically takes 3-5 days in clinical laboratories and has >95% accuracy when performed according to established protocols.

Why It Matters

MSI testing has transformed cancer management by identifying patients who benefit from specific treatments and surveillance. For Lynch syndrome carriers, MSI detection enables early cancer screening and preventive measures, reducing mortality by up to 60%. In treatment, MSI-high tumors often respond poorly to conventional chemotherapy but show remarkable responses to immunotherapy drugs like pembrolizumab, with response rates of 40-50% compared to 0-5% in MSI-stable tumors. This has led to tissue-agnostic FDA approvals, where treatment decisions are based on molecular markers rather than tumor origin. Additionally, MSI status affects prognosis—MSI-high colorectal cancers generally have better stage-specific survival but worse outcomes if treated with 5-FU chemotherapy alone. The economic impact is significant too, with MSI testing preventing unnecessary chemotherapy in responsive patients, saving healthcare costs while improving outcomes.